INDIANAPOLIS, June 29, 2018 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) announced today initiation of the
ObserVational Survey of the Epidemiology,
tReatment and Care Of MigrainE
(OVERCOME) study, which aims to be the largest study of its kind in
the field of migraine, engaging 40,000 people with migraine
throughout the U.S. during the next two years. The objectives of
the study are to further understand the burden of migraine and the
stigma experienced by people living with migraine, identify
barriers to the use of preventive and acute treatments for migraine
and to assess how the introduction of novel preventive and acute
treatment options may influence delivery of migraine care and costs
of care in real-world settings.
"Though more than 36 million Americans are living with migraine,
there is a lack of recognition and appreciation for the burden and
impact of this neurobiological disease," said Eric Pearlman, M.D., Ph.D., medical fellow, Eli
Lilly and Company. "As a potential new generation of treatments
become available for migraine, we need a new conversation to
appropriately frame the burden of the disease and the benefits of
optimal treatment."
The OVERCOME study is a two-year, multi-wave prospective,
web-based patient survey that leverages learnings from the American
Migraine Prevalence and Prevention Study (AMPP), the seminal,
longitudinal, population-based migraine study initiated in 2004.
Baseline data from OVERCOME will be available in 2019, and data
collection on the study is expected to end in 2022.
"This type of research – and at this scale – is crucial to our
continued understanding of migraine and to inform clinical practice
and patient access as treatment evolves," said the chair of the
study's Scientific Advisory Panel, Richard
B. Lipton, M.D., professor of Neurology, professor of
Epidemiology and Population Health and director of Montefiore
Headache Center, Albert Einstein College Of Medicine. "With the
AMPP Study, we aspired to understand the life course of migraine,
the patterns of treatment and the effect of treatment on the
patient journey. OVERCOME builds on insights from the AMPP Study
and seeks to provide an up-to-date, comprehensive view of migraine,
particularly in light of recent and emerging therapeutic
innovations."
The OVERCOME study is being conducted by Kantar Health on behalf
of Eli Lilly and Company with expert guidance provided by some of
the leading voices in migraine research today, including:
- Dawn C. Buse, Ph.D., clinical
professor of Neurology at the Albert Einstein College of Medicine,
assistant professor in the Clinical Health Psychology Doctoral
Program of the Ferkauf Graduate School of
Psychology, Yeshiva University
- Michael L. Reed, Ph.D., managing
director of Vedanta Research
- Richard B. Lipton, M.D.,
professor of Neurology, professor of Epidemiology and Population
Health and director, Montefiore Headache Center, Albert Einstein
College Of Medicine
- Robert E. Shapiro, M.D., Ph.D.,
professor of Neurological Sciences, Robert
Larner, M.D., College of Medicine at The University of Vermont
- Sait Ashina, M.D., director of
Comprehensive Headache Center, Departments of Neurology and
Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess
Medical Center, Harvard Medical
School
About the OVERCOME Study
The OVERCOME study will
enroll two 20,000-person population samples to be followed
longitudinally for two years. The first population sample will
begin enrollment in August 2018 to
establish the baseline, followed by enrollment of the second
population sample after the broad availability of the
anti-calcitonin gene-related peptide (CGRP) class of medications, a
new generation of preventive treatments for migraine, and potential
advances in acute treatments for migraine.
About Lilly's Commitment to Headache Disorders
For
more than 25 years, Lilly has been committed to helping people
suffering from headache disorders, investigating more than a dozen
different compounds for the treatment of migraine, cluster headache
and other disabling headache disorders. These research programs
have accelerated the understanding of these neurobiological
diseases and furthered the advancement of Lilly's comprehensive
late-stage development programs for the prevention of migraine and
cluster headache, and for the acute treatment of migraine. Our goal
is to make life better for people with headache disorders by
offering comprehensive solutions to prevent or stop these disabling
diseases. The combined clinical, academic and professional
experience of our experts helps us to build our research portfolio,
identify challenges for healthcare providers and pinpoint the needs
of patients living with migraine and cluster headache.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
www.lilly.com/newsroom/social-channels. P-LLY
Refer to: Jen Dial; dial_jennifer_kay@lilly.com;
317-220-1172 (Lilly Bio-Medicines)
View original content with
multimedia:http://www.prnewswire.com/news-releases/lilly-announces-initiation-of-the-observational-survey-of-the-epidemiology-treatment-and-care-of-migraine-overcome-to-advance-understanding-of-burden-impact-and-epidemiology-of-migraine-300674138.html
SOURCE Eli Lilly and Company